QC
KALV

Quadrature Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Quadrature Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$707K Buy
+35,123
New +$566K 0.01% 676
2025
Q3 		– Sell
-19,973
Closed -$226K – 1274
2025
Q2 		$226K Buy
+19,973
New +$244K ﹤0.01% 780

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrature Capital's KALV Position: Q1 2026 in Review

Quadrature Capital opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 35,123 shares worth $707K. The stake represents 0.01% of the portfolio and ranks #676 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in KALV as recently as Q2 2025.

Quadrature Capital first reported a position in KALV in Q2 2025 and has held it in 2 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Quadrature Capital held 35,123 shares of KalVista Pharmaceuticals worth $707K as of Q1 2026.
  • KalVista Pharmaceuticals was a new Quadrature Capital position in Q1 2026.
  • KalVista Pharmaceuticals made up 0.01% of Quadrature Capital's portfolio in Q1 2026, its #676 holding.
  • Quadrature Capital first reported a position in KalVista Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.